n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, January 15th, 2016

The QualityStocks
Daily Stock List

graphic
graphic

Kaya Holdings, Inc. (KAYS)

Cannabis Financial Network News, Wealth Daily, SmallCapVoice and Alternative Fuels Americas reported on Kaya Holdings, Inc. (KAYS), and we are reporting on the Company as well, here at the QualityStocks Daily Newsletter.

Kaya Holdings, Inc. through its subsidiary, Marijuana Holdings Americas, Inc. (MJAI), owns and operates Kaya Shack™. This is the first legal marijuana dispensary by a fully reporting U.S. public company. The Company was formerly known as Alternative Fuels America, Inc. It changed its corporate name to Kaya Holdings, Inc. in April 2015. Listed on the OTCQB, Kaya Holdings has its headquarters in Fort Lauderdale, Florida.

The Company changed its name to reflect its 100 percent focus on continuing to develop its current cannabis operations. Kaya owns and operates Kaya Shack, a fully legal medical marijuana dispensary in Portland, Oregon. Kaya Shack was established to create a nation-wide brand for the developing legal marijuana community.

Kaya Holdings’ vision is a national chain of Kaya Shack stores, available to those legally free to access high quality marijuana for their personal use - whether medicinal or recreational, in accordance with local laws.

Kaya Shack products include Accessories, Apparel, Concentrates, Creams, Flower, and Edibles (cannabis-infused baked goods and candies). By way of its Kaya Farms Grow operations, Kaya creates and establishes its own brands that produce, distribute and/or sell premium cannabis products.

The Company’s flagship Hawthorne Boulevard Store opened on July 3, 2014. The location is in an area that many call “the Greenwich Village of Portland”. The Portland facility presently features more than 35 popular strains of marijuana. This includes Kaya’s proprietary, high-grade “Kaya Kush”. Moreover, Kaya’s stores feature different concentrates, including butane hash oil (B.H.O.) and CO2 oil extract (wax, shatter) that range in potency from around 40 percent to more than 80 percent THC, and also high grade Oils and Tinctures, high CBD – low THC strains and “Kaya Candies”, “Kaya Caramels” and a variety of cookies and cakes for non-smoker patients.

This past November, Kaya Holdings announced that it released its quarterly report for the period ending September 30, 2015. During this quarter Kaya operated its Medical Marijuana Facility in Portland, transitioned the Portland location to a recreational outlet, opened a second store in Salem (also recreational) and significantly upgraded its consolidated Grow.

Kaya Holdings, Inc. (KAYS), closed Friday's trading session at $0.0946, up 11.95%, on 398,124 volume with 42 trades. The average volume for the last 60 days is 159,906 and the stock's 52-week low/high is $0.05/$0.15.

Daniels Corporate Advisory Company, Inc. (DCAC)

MyBestStockAlerts, eliteotc.com, WINNINGOTC, Wall Street Beauties, HEROSTOCKS, Stock Brain, Newsletter, PennyStockPower, ShazamStocks, and Information Solutions Group reported on Daniels Corporate Advisory Company, Inc. (DCAC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Established in 2002, Daniels Corporate Advisory Company, Inc. is a corporate strategy and business incubation enterprise. The Company acquires niche business opportunities in predetermined industries. Daniels’ provides capital, human resources, marketing concepts and sales strategies to each of their target acquired business entities. The Company serves the needs of small, growing public and private companies through customized financial, operational, and business strategy initiatives. Daniels provides clients with strategies designed to nurture and speed up their growth in new or existing niche markets. The OTC BB-listed Company is headquartered in Forest Hills, New York.

The strategies that Daniels provides include joint-ventures (JVs), marketing opportunities, partnerships, and potential acquisitions. Furthermore, it secures growth capital and engages in the placement of senior-level team members. Daniels positions a professional team, each with business acumen suited to a specific acquired industry segment, working meticulously in providing collective expertise with the goal of adding growth and earnings.

Daniels incubates new and existing companies as subsidiaries. This includes creating first-class personnel teams and premier go-to-market strategies, and also providing the above-mentioned growth capital.

The Company funds their growth with capital raised from the sale of Daniels’ registered common stock until the time when the incubated company is viable, profitable, revenue-generating, and completely self-sufficient. Upon being viable, the subsidiary is spun-off to the independent contractors’ instrumental in its operation and expansion, and to the shareholder base of Daniels Corporate Advisory Company and Daniels itself.

Daniels established the Food and Beverage Group in July 2015. The Company has announced that the Food and Beverage Group would center on acquiring Italian Cafés and Clubs with Entertainment in the New York metropolitan area.

In October 2015, Daniels Corporate Advisory Company announced that it was conducting negotiations and due diligence on two promising Italian Café acquisitions by the Company’s Food and Beverage Group.  Together, the two Italian Cafés generate $1 million in yearly sales with approximately $300,000 EBITDA.  The Cafés are both on Long Island’s affluent North Shore.

In essence, Daniels limits overall risk associated with start-ups through selecting candidates with new products and services (which are already part of an existing product mix that is successful in its own right). As an example, the Company says that a foreign product manufacturer, successful in its own country, can launch that product in the U.S. via a Sales Agency Relationship with Daniels Corporate Advisory Company.

Daniels Corporate Advisory Company, Inc. (DCAC), closed Friday's trading session at $0.00118, up 18.00%, on 10,772,137 volume with 58 trades. The average volume for the last 60 days is 14,159,866 and the stock's 52-week low/high is $0.0008/$0.18.

KollagenX Corp. (KGNX)

StreetAuthorityFinancial and MoneyTV reported this week on KollagenX Corp. (KGNX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Founded in 2008, KollagenX Corp. is an advanced skin care development and marketing enterprise. The Company’s main emphasis is nano gold technology, also called NGT®. KollagenX® develops and introduces new, safe, more affordable eco-friendly NGT® products that it believes will help improve the quality of lives. KollagenX is headquartered in Chino Hills, California. The Company formerly went by the name Integrated Electric Systems Corp. It changed its name to KollagenX Corp. in July 2014. KollagenX’s shares trade on the OTC Markets’ OTCQB.

KollagenX® helps bring the nourishment one’s skin requires to be healthier and function more effectively. The Company says that its innovative anti-aging skin care products restore a natural youthful glow and a smoother, suppler appearance. KollagenX® Nano Gold Technology (NGT®) has recognition for its ability to ward off UV damage, tighten lax skin, and reduce the appearance of discoloration spotted skin. This is in addition to its antioxidant and antimicrobial abilities.

The Company indicates that KollagenX® (NGT®) promotes increased circulation, assists in eliminating toxins from the body, and hastens tissue repair. It promotes the growth of the skin cells through replacing the aging cells for revitalization. The Company’s Collection includes 24KT Gold Face Mask, 24KT Gold Under-Eye’s, 24KT Gold Eye Serum, 24KT Gold Hydrating Cream, 24KT Gold Cleanser, and 24KT Gold Lip Gloss.

KollagenX Nano Gold is 99.999 percent pure gold. It is free of any hazardous metal elements. In addition, it is 1/2000 the size of an average pore, therefore easily penetrating into the dermis. KollagenX® has received approval for their 24KT Nano Gold product line from the Ministry of Health of Kuwait. Approval was granted to import product to Kuwait.

In November 2015, KollagenX announced that its Management engaged Samson Pharmaceuticals to expand its 24KT Gold Skin Care Collection. KollagenX’s belief is that Samson Pharmaceuticals is the right fit for KollagenX®.  Samson Pharmaceuticals is Food and Drug Administration (FDA registered) and a drug licensed laboratory in the United States currently manufacturing a diverse line of products ranging from OTC (Over-the-Counter), cosmetics, dietary supplements and others.

This week, KollagenX released a corporate update on the manufacturing of 300,000 Units, Costco packaging, as well as Jessica Alba using the NanoGold product. KollagenX Chief Executive Officer, Mr. Rondell Fletcher covered 2016 with Mr. Donald Baillargeon of MoneyTV on KollagenX’s direction centered on retail outlets.

KollagenX Corp. (KGNX), closed Friday's trading session at $0.131, down 4.38%, on 98,721 volume with 20 trades. The average volume for the last 60 days is 118,620 and the stock's 52-week low/high is $0.095/$0.85.

NuGene International, Inc. (NUGN)

SmallCapVoice reported earlier on NuGene International, Inc. (NUGN), and we report on the Company today, here at the QualityStocks Daily Newsletter.

NuGene International, Inc. specializes in developing, manufacturing, and marketing proprietary regenerative cosmeceutical and pharmaceutical products. These are based on adipose derived human stem cells and human stem cell media. The Company’s goal is to take advantage of its wide-ranging knowledge and expertise to develop age defying regenerative cosmeceutical skincare and hair care products, and additionally pharmaceutical products based on the same regenerative science platform.

NuGene BioPharma, Inc. is the Company’s subsidiary. NuGene BioPharma has acquired all rights, title and interest in and to SkinGuardian®, a Food and Drug Administration (FDA)-approved (monographed) skin protectant, antiseptic, and moisturizing topical cream. It acquired all intellectual property (IP) held by SkinGuardian and its Founder and Owner, Mr. Chris O'Brien, relating to the SkinGuardian technology and applications.

The basis of NuGene kathy ireland's cosmeceutical and pharmaceutical products are on proprietary stem cell based regenerative formulations derived from non-controversial, adult human stem cell derived media obtained from adipose tissue. NuGene kathy ireland's exclusive products combine its in-house advancements, proprietary technologies, and patent pending formulations. NuGene International has four patents pending covering 15 innovative applications. NuGene’s products include its Skin Care Collection and its Hair Care Collection.

NuGene has filed new patents to protect proprietary claims directed to bandages treated with Human Adipose Derived Stem Cell Cultured (HADSCC) media in a variety of formats. This includes nanoencapsulated media dried to the dressings. Patent applications were filed for burn, scar and wound healing aids and bandages.

NuGene has announced the conclusions of an independent clinical study. The independent clinical study concludes that NuGene serum activates multiple anti-aging genes. The study was conducted by Genemarkers LLC (GM), an independent clinical laboratory equipped to analyze gene expression in the human body.

Recently, NuGene International announced that it signed an agreement with Mr. Kevin Harrington, Original Shark from the hit ABC show Shark Tank, to lead the launch of the new NuGene kathy ireland retail product line. He will also assist NuGene International with future fund raising efforts. Mr. Harrington has launched over 500 products, which have generated greater than $5 billion in global sales.

NuGene International, Inc. (NUGN), closed Friday's trading session at $1.03, down 0.96%, on 28,385 volume with 30 trades. The average volume for the last 60 days is 44,548 and the stock's 52-week low/high is $0.26/$5.00.

AdvanSource Biomaterials Corp. (ASNB)

TopPennyStockMovers, Zacks, and Nebula Stocks reported on AdvanSource Biomaterials Corp. (ASNB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

AdvanSource Biomaterials Corp. is an ISO certified materials technology company. Specialists in polyurethane technologies, the Company provides a variety of material formats for use in long and short term implants and also disposable products. The Company previously went by the name CardioTech International, Inc. It changed its name to AdvanSource Biomaterials Corp. in October of 2008. The Company is based in Wilmington, Massachusetts.

AdvanSource Biomaterials develops advanced polymer materials. These polymer materials provide vital characteristics in the design and development of medical devices. The Company’s biomaterials are used in devices designed for treating a wide array of anatomical sites and disease states. AdvanSource’s business model takes advantage of its proprietary materials science technology and manufacturing expertise to expand its product sales and royalty and license fee income.

The Company’s pioneering technology includes products such as ChronoFlex, HydroMed, and HydroThane. The technology has been developed to overcome a broad spectrum of design and functional challenges, from the need for dimensional stability, ease of manufacturability and demanding physical properties to overcoming environmental stress cracking and providing heightened lubricity for ease of insertion.

AdvanSource Biomaterials manufactures and sells its custom polymers under the trade names ChronoFilm, ChronoFlex, ChronoThane, ChronoPrene, ChronoSil, HydroThane, and PolyBlend. Its new product extensions enable it to customize its proprietary polymers for specific customer applications in a broad array of device categories.

The Company manufactures and sells its proprietary HydroThane polymers to medical device manufacturers that are evaluating HydroThane for use in their products. In addition, it manufactures specialty hydrophilic polyurethanes, which are mainly sold to customers as part of exclusive arrangements.

The Company’s HydroThane is a thermoplastic, water-absorbing, polyurethane elastomer. It possesses properties that AdvanSource Biomaterials believes make it well-suited for the complex needs of an assortment of catheters. Additionally, it believes HydroThane exhibits an inherent degree of bacterial resistance, clot resistance, and biocompatibility. HydroThane has elastic properties similar to living tissue when hydrated.

Last month, AdvanSource Biomaterials announced it entered into a multi-year supply agreement with an international leader in radiography and imaging technology. The Agreement provides for year over year volume increases of a custom developed polyester urethane product line.  Khristine Carroll, AdvanSource Biomaterials’ SVP of Commercial Operations, stated, “We are very pleased at the partnership we have developed with this valued customer, a leader in the imaging and radiography market.”

AdvanSource Biomaterials Corp. (ASNB), closed Friday's trading session at $0.3099, down 7.19%, on 59,928 volume with 24 trades. The average volume for the last 60 days is 63,491 and the stock's 52-week low/high is $0.021/$0.41.

graphic

The QualityStocks
Company Corner

graphic
graphic

Avant Diagnostics, Inc. (AVDX)

The QualityStocks Daily Newsletter would like to spotlight Avant Diagnostics, Inc. (AVDX). Today, Avant Diagnostics, Inc. closed trading at $0.21, up 5.00%, on 196 volume with 2 trades. The stock’s average daily volume over the past 60 days is 1,396, and its 52-week low/high is $0.20/$1.95.

Avant Diagnostics, Inc. announce today that CEO Gregg Linn will be presenting at the NobleCon12 - Noble Financial Capital Marketsí Twelfth Annual Investor Conference at in Sandpiper Bay, Florida, on Tuesday, January 19, 2016 at 2:00PM Eastern Standard Time.

Avant Diagnostics, Inc. (AVDX) is a medical diagnostic technology company that specializes in large panel biomarker screening. The company's first test, OvaDx®, is a sophisticated microarray-based test designed to detect pre-symptomatic ovarian cancer by measuring the activation of the immune system in blood samples in response to early stage ovarian tumor cell development.

In clinical development, OvaDx has indicated high sensitivity and specificity for all types and stages of ovarian cancer, including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous and ovarian adenocarcinoma. Upon FDA approval, Avant plans to offer its diagnostic product as an elective test for women seeking greater wellness, as well as those in the elevated risk category for ovarian cancer.

OvaDx is also expected to be used by doctors to advance the forefront of ovarian cancer treatment, promoting the utilization of improved surgical options and more effective chemotherapies by serving as a supplement to existing tests, such as CA-125, OVA1® and transvaginal ultrasound. In this way, Avant's innovative product will promote earlier diagnoses and, as a result, improved survival rates for patients with ovarian cancer.

As it continues to seek FDA approval for its groundbreaking diagnostic technology, Avant is poised to promote considerable growth in the ovarian cancer market, addressing what is currently the most deadly cancer of the female reproductive system. The company will lean on the industry experience of its management team in order to continue positioning itself for long-term success in the medical diagnostic market. Disclaimer

Avant Diagnostics, Inc. Company Blog

Avant Diagnostics, Inc. News:

Avant Diagnostics to Attend 12th Annual Noble Capital Markets Conference

Avant Diagnostics, Inc. Announces Launch of New Corporate Website

Avant Diagnostics Inc. Receives FDA IRB Approval for OvaDx(R) Ovarian Cancer Validation Test Specimens

Agora Holdings, Inc. (AGHI)

The QualityStocks Daily Newsletter would like to spotlight Agora Holdings, Inc. (AGHI). Today, Agora Holdings, Inc. closed trading at $0.16, up 23.08%, on 27,863 volume with 13 trades. The stock’s average daily volume over the past 60 days is 20,934, and its 52-week low/high is $0.03/$2.50.

Agora Holdings, Inc. (AGHI), together with its wholly-owned subsidiary, Geegle Media, is leading a diversified family entertainment and media enterprise through business segments which include: TV on Demand, interactive media, business products and consumer platforms. With its multi-dimensional approach, Geegle Media supports Agora Holdings' mission to deliver innovate and high-quality business solution products and to deliver video content from around the world.

Geegle Media web platforms include; GeegleTV, Frame, 1000Salads, RealtyTV and LobbyTV. Geegle TV is a multi-platform video entertainment website that curates high-quality video content from around the world. In 2016, GeegleTV will serve as co-producer by airing original content. By exposing undiscovered content to millions of users and rendering it shareable to social media, Geegle TV will serve as a marketing partner to local and internationally based TV shows not yet on the open market.

For commercial use, Geegle Media provides a variety of solutions that include web development and billing software for VoIP applications. RealtyTV is its state-of-the-art platform for real estate brokerages. LobbyTV is another of its widely used products by business offices. For individuals, Geegle TV combines radio, On Demand movies, news, sports and children's content.

Geegle Media is also developing 1000salads, an online hub that encourages healthy lifestyles. The portal will feature recipes and products, health-oriented articles and a curated selection of local restaurants and grocers that deliver to the health-conscious user. Currently in its alpha stage of development, 1000salads is gearing up its sales and marketing in preparation for its launch in 2016.

Geegle Media differs from other On Demand providers, such as Netflix and HBO, in that its service is free of constraints such as subscription, fees and penalties. As consumers increasingly opt for personalized sources of entertainment, Agora recognizes the vast opportunities and growth potential provided by the rising popularity of TV On Demand. The company also benefits from strong and visionary management with a track record of bringing innovative ideas to fruition. Disclaimer

Agora Holdings, Inc. Company Blog

Agora Holdings, Inc. News:

Agora Holdings, Inc. (AGHI) Announces Engagement of QualityStocks Corporate Communications Suite

Agora Holdings, Inc.'s Geegle Media Develops TECH, a Workflow Management Software

Agora Holdings Inc.'s Geegle TV Devising Monetizing Plan for Its Real TV Project

International Stem Cell Corp. (ISCO)

The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $2.70, up 14.89%, on 6,766 volume with 26 trades. The stock’s average daily volume over the past 60 days is 15,219, and its 52-week low/high is $1.25/$11.625.

International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent portfolio offering clean intellectual property and freedom to operate. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

The company’s human stem cells have been shown to be as pluripotent as embryonic stem cells, however their creation does not involve the destruction of a viable human embryo, which effectively sidesteps the controversy and ethical dilemmas associated with the use of human embryonic stem cells. In contrast to induced pluripotent stem cells, ISCO’s stem cells do not involve manipulation of cells’ genome thereby avoiding potential safety and regulatory obstacles in clinical applications.

The company's scientists are currently focused on using its stem cells to treat severe unmet medical needs of the central nervous system (Parkinson’s disease), the liver and the eye, where cell therapy has been clinically proven but is limited due to the unavailability of safe human cells. Once the technology has been clinically validated there are an essentially unlimited number of potential applications. Because of their immune-matching ability a relatively small number of these stem cell lines could offer the potential of producing the first true stem cell bank as a means of serving populations of different immune types across the globe.

In addition to its therapeutic focus, ISCO also provides a growing revenue stream through two wholly owned subsidiaries. Lifeline Cell Technology specializes in producing primary human cells and growth media for biological research, and Lifeline Skin Care, the company manufactures and markets advanced anti-aging skincare products utilizing the company’s expertise in stem cell biology. Disclaimer

International Stem Cell Corp. Company Blog

International Stem Cell Corp. News:

International Stem Cell Corporation Signed a Clinical Service Agreement With the Florey Institute of Neuroscience and Mental Health

International Stem Cell Corporation Receives Authorization to Initiate Phase I/IIa Clinical Trial of ISC-hpNSC for the Treatment of Parkinson's Disease

International Stem Cell Corporation Announces Launch Plans for New Nano-Compound Products

Legacy Ventures International, Inc. (LGYV)

The QualityStocks Daily Newsletter would like to spotlight Legacy Ventures International, Inc. (LGYV). Today, Legacy Ventures International, Inc. closed trading at $1.08, up 13.68%, on 22,814 volume with 35 trades. The stock’s average daily volume over the past 60 days is 38,935, and its 52-week low/high is $0.01/$2.50.

Legacy Ventures International, Inc. (LGYV) is an investment company seeking out high-potential businesses with big ideas that can be scaled in order to promote hyper growth. The company fuels innovation and passion by providing the capital, oversight and connections that young businesses need to reach their full potential.

Legacy is led by a highly-qualified executive team with decades of relevant industry experience. Evan Clifford, the company's chief executive officer, has spent more than 15 years building and maintaining relationships with some of North America's most influential executives. Over the past decade, he has served as a lead advisor to a collection of companies and individuals striving for personal and professional success. Likewise, Rehan Saeed, Legacy's chief financial officer, has over a decade of experience in the banking industry during which he built and managed a real estate portfolio valued at $110 million.

The company's current brand portfolio is headlined by newly-acquired RM Fresh Brands, a servicer of food and beverage retailers and distributors around the globe. RM Fresh Brands takes a unique approach to brand partnerships by maintaining a clear focus on sustainable, category-changing consumables. This strategy has helped it build an extensive portfolio of highly-desirable brands – including Boxed Water, Aloe Gloe, Uncle Si's Iced Tea and Chef 5-Minute Meals.

Following the successful acquisition of RM Fresh Brands, Legacy is in a strong strategic position to move forward with its efforts to promote sustainable growth. The company will lean on the considerable experience of its management team as it looks to build on its recent progress while promoting maximized shareholder value. Disclaimer

Legacy Ventures International, Inc. Company Blog

Legacy Ventures International, Inc. News:

Legacy Ventures Appoints New Director

Legacy Ventures Closes Funding

Legacy Ventures Welcomes G. Scott Paterson to the Advisory Committee

Nutra Pharma Corp. (NPHC)

The QualityStocks Daily Newsletter would like to spotlight Nutra Pharma Corp. (NPHC). Today, On the Move Systems, Inc. closed trading at $0.025, up 6.84%, on 270,332 volume with 16 trades. The stock’s average daily volume over the past 60 days is 306,685, and its 52-week low/high is $0.0025/$0.27.

Nutra Pharma Corp. (NPHC) is a biotech company working in collaboration with its subsidiaries to develop an innovative pipeline of biopharmaceutical products for the management of neurological disorders, cancer, autoimmune, and infectious diseases. At the core of Nutra Pharma's intellectual property is a unique platform for extracting neurotoxins from Asian cobra venom and transforming them into non-toxic therapeutics.

The ReceptoPharm subsidiary, Nutra Pharm's drug discovery arm, is focused on the development of new therapeutic agents based upon specialized receptor-binding proteins found in nature, especially those found in snake venom from the cobra. ReceptoPharm's R&D pipeline consists of several novel therapies in various stages of development to prevent and/or treat multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN), herpes, rheumatoid arthritis (RA) and pain. The subsidiary also provides small and start-up biotech companies a full range of contract research services through its ISO class 5 and GMP certified facilities in Plantation, Florida.

Nutra Pharma recently received Orphan Drug Status from the FDA for the treatment of pediatric MS for its drug, RPI-78M. The designation of RPI-78M as an Orphan Drug provides Nutra Pharma with a seven-year period of market exclusivity in the U.S. once the drug is approved. Additional benefits over conventional drug applications include: tax credits for clinical research costs, the ability to apply for grant funding, clinical trial design assistance, plus assistance from the FDA in the drug development process and the waiver of Prescription Drug User Fee Act (PDUFA) filing fees which could be in excess of $2.5 million. The granting of Orphan Drug Designation allows Nutra Pharma to move forward with its preparation of an Investigative New Drug Application and proposal of clinical trials. The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics.

ReceptoPharm holds all of the intellectual property for Nutra Pharma's drug pipeline, while Nutra Pharma directly holds all of the property dealing with their over-the-counter drugs. This includes Nyloxin, an OTC pain reliever for humans, and Pet Pain-Away, a pain reliever for dogs and cats. The company's Nyloxin product is the first OTC pain reliever clinically proven to treat moderate to severe chronic pain. The drug is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

Nutra Pharma is a revenue-generating company with 12 patents and patents pending, three completed phase 1/phase 2 clinical trials, and 12 FDA-registered OTC products in the United States. The company also has regulatory clearance for Nyloxin in India, where management believes its initial distribution streams could become the company's biggest market. Management is also defining its plan to expand into China and Canada while strengthening its position the United States. Disclaimer

Nutra Pharma Corp. Company Blog

Nutra Pharma Corp. News:

Nutra Pharma CEO, Rik J Deitsch, Has Published a Letter to Shareholders Outlining the Current Efforts and the Future Goals of the Company

Nutra Pharma Corp. (NPHC) CEO Featured in Exclusive QualityStocks Interview

Nutra Pharma Corp. (NPHC) Announces Engagement of QualityStocks Corporate Communications Suite

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

QualityStocks
(ISGN)

2.

TheNextBigTrade
(AXIO)

3.

Tip.us
(CANV)

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251